ARDELYX, INC. Proceeds from Issuance of Secured Debt
ARDELYX, INC. (ARDX) reported Proceeds from Issuance of Secured Debt of $81.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSecuredDebt · last filed 2026-08-06
- ARDELYX, INC. proceeds from issuance of secured debt for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ARDELYX, INC. proceeds from issuance of secured debt for the quarter ending 2025-09-30 was $0.00.
- ARDELYX, INC. proceeds from issuance of secured debt for the quarter ending 2025-06-30 was $48.67M.
- ARDELYX, INC. proceeds from issuance of secured debt for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- ARDELYX, INC. proceeds from issuance of secured debt for fiscal 2025 was $48.67M, a 51.06% decline from fiscal 2024.
- ARDELYX, INC. proceeds from issuance of secured debt for fiscal 2024 was $99.45M, a 344.26% increase from fiscal 2023.
- ARDELYX, INC. proceeds from issuance of secured debt for fiscal 2023 was $22.39M, a 17.00% decline from fiscal 2022.
- ARDELYX, INC. proceeds from issuance of secured debt for fiscal 2022 was $26.97M.
| Period end | Proceeds from Issuance of Secured Debt 3 month | Proceeds from Issuance of Secured Debt 6 month | Proceeds from Issuance of Secured Debt 9 month | Proceeds from Issuance of Secured Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $81.87M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $48.67M derived: sum of 3 quarters · filed 2026-08-06 | $48.67M 10-K · filed 2026-02-19 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $48.67M derived: sum of 2 quarters · filed 2026-08-06 | $48.67M 10-Q · filed 2025-10-30 | $98.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $48.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $48.67M 10-Q · filed 2026-08-06 | $98.37M derived: sum of 3 quarters · filed 2026-08-06 | $98.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-01 | $49.70M derived: sum of 2 quarters · filed 2026-02-19 | $49.70M derived: sum of 3 quarters · filed 2026-02-19 | $49.70M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-12-31 | $49.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $49.70M derived: sum of 2 quarters · filed 2026-02-19 | $49.70M derived: sum of 3 quarters · filed 2026-02-19 | $99.45M 10-K · filed 2026-02-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $49.75M 10-Q · filed 2025-10-30 | $72.14M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $49.75M 10-Q · filed 2025-08-04 | $72.14M derived: sum of 3 quarters · filed 2026-02-19 | $72.14M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $49.75M 10-Q · filed 2025-05-01 | $72.14M derived: sum of 2 quarters · filed 2026-02-19 | $72.14M derived: sum of 3 quarters · filed 2026-02-19 | $72.14M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $22.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $22.39M derived: sum of 2 quarters · filed 2026-02-19 | $22.39M derived: sum of 3 quarters · filed 2026-02-19 | $22.39M 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | $0.00 derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | $0.00 derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | $0.00 derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | $26.97M 10-K · filed 2025-02-20 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $0.00 derived: sum of 2 quarters · filed 2023-10-31 | $26.97M 10-Q · filed 2023-10-31 | $26.97M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $26.97M 10-Q · filed 2023-08-02 | $26.97M derived: sum of 3 quarters · filed 2024-02-22 | $26.97M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $26.97M 10-Q · filed 2023-05-03 | $26.97M derived: sum of 2 quarters · filed 2024-02-22 | $26.97M derived: sum of 3 quarters · filed 2024-02-22 | $26.97M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |